Future research should aim to elucidate the subtype-specific regulatory mechanisms of MTA3 across lymphoma entities, characterize the molecular basis of its interaction with BCL6, and evaluate the therapeutic potential of targeting the MTA3-BCL6 axis in precision oncology approaches (see Table 1, Figure 3). The gene discussed is MTA3; the disease is lymphoma.